Alexander A. Fitzpatrick Esq., J.D. serves as Executive Vice President, General Counsel, Secretary of the Company. Mr. Fitzpatrick is responsible for our corporate governance, legal, corporate development, intellectual property and risk management functions. Prior to joining Evofem, Mr. Fitzpatrick served as Chief Legal Officer of Kyriba Corporation from 2014 to 2015 and Senior Vice President, General Counsel, Compliance Officer and Secretary of Verenium Corporation, a publicly traded biotechnology company from 2010 to 2014. Prior to that, Mr. Fitzpatrick served as Senior Vice President, General Counsel and Secretary of Kintera, Inc., a publicly traded technology company. Following the sale of Kintera, Mr. Fitzpatrick continued to serve in a similar position for a major division of Blackbaud, Inc. Prior to that, as a member of the business, corporate and technology departments with the law firms Cooley LLP and Latham & Watkins LLP in San Diego, and Rogers & Wells LLP (now Clifford Chance) in London, Mr. Fitzpatrick represented pharmaceutical and other technology companies, investment banks and venture capitalists in a variety of transactions including numerous collaborations, mergers and acquisitions, intellectual property matters, licensing and financing activity. Mr. Fitzpatrick received a B.S. in mathematics from Georgetown University and a J.D. from the University of California, Berkeley.
What is Alexander A. Fitzpatrick's net worth?
The estimated net worth of Alexander A. Fitzpatrick is at least $403.91 as of September 28th, 2023. Mr. Fitzpatrick owns 42,969 shares of Evofem Biosciences stock worth more than $404 as of December 23rd. This net worth estimate does not reflect any other assets that Mr. Fitzpatrick may own. Learn More about Alexander A. Fitzpatrick's net worth.
How do I contact Alexander A. Fitzpatrick?
Has Alexander A. Fitzpatrick been buying or selling shares of Evofem Biosciences?
Alexander A. Fitzpatrick has not been actively trading shares of Evofem Biosciences over the course of the past ninety days. Most recently, on Monday, December 20th, Alexander A. Fitzpatrick bought 200 shares of Evofem Biosciences stock. The stock was acquired at an average cost of $48.75 per share, with a total value of $9,750.00. Learn More on Alexander A. Fitzpatrick's trading history.
Who are Evofem Biosciences' active insiders?